Biocon to launch insulin glargine for Australia

Nearly 200 million people in Australia suffer from diabetes and 280 are diagnosed of the disease daily.

Published: 05th October 2019 01:28 AM  |   Last Updated: 05th October 2019 09:16 AM   |  A+A-

By Express News Service

BENGALURU: India’s biopharma major Biocon Ltd has announced the launch of an insulin glargine called Semglee, in partnership with global pharma firm Mylan. Insulin glargines are man-made versions of human insulin. Semglee is used to treat Type-1 diabetes in adults and children above the age of six years, and Type-2 diabetes. The insulin biosimilar would be available in Australia under the Pharmaceutical Benefit Scheme (PBS) that helps manage the growing costs of that country’s healthcare.

Biosimilars have revolutionised global pharma markets by offering cheap alternatives in treatment of chronic disorders such as diabetes. The total annual cost of the impact of diabetes in Australia is estimated to be worth $14.6 billion. Nearly 200 million people in Australia suffer from diabetes and 280 are diagnosed of the disease daily.

The Australian government had in 2018 announced $5 million to undertake activities that facilitate the prescribing, dispensing and use of biosimilar medicines under the Biosimilars Awareness Initiative.

“As a leading global insulin player, Biocon has been addressing the needs of patients with diabetes for over 15 years and we are confident that availability of Semglee through the Pharmaceutical Benefits Scheme will expand patients’ access to this therapy in Australia and reduce the cost burden for PBS,” said Christiane Hamacher, CEO, Biocon Biologics.


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp